Literature DB >> 10207063

Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain.

G Selivanova1, L Ryabchenko, E Jansson, V Iotsova, K G Wiman.   

Abstract

A synthetic 22-mer peptide (peptide 46) derived from the p53 C-terminal domain can restore the growth suppressor function of mutant p53 proteins in human tumor cells (G. Selivanova et al., Nat. Med. 3:632-638, 1997). Here we demonstrate that peptide 46 binds mutant p53. Peptide 46 binding sites were found within both the core and C-terminal domains of p53. Lys residues within the peptide were critical for both p53 activation and core domain binding. The sequence-specific DNA binding of isolated tumor-derived mutant p53 core domains was restored by a C-terminal polypeptide. Our results indicate that C-terminal peptide binding to the core domain activates p53 through displacement of the negative regulatory C-terminal domain. Furthermore, stabilization of the core domain structure and/or establishment of novel DNA contacts may contribute to the reactivation of mutant p53. These findings should facilitate the design of p53-reactivating drugs for cancer therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10207063      PMCID: PMC84132          DOI: 10.1128/MCB.19.5.3395

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  27 in total

1.  Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus.

Authors:  J Jayaraman; C Prives
Journal:  Cell       Date:  1995-06-30       Impact factor: 41.582

2.  Solution structure of the tetrameric minimum transforming domain of p53.

Authors:  W Lee; T S Harvey; Y Yin; P Yau; D Litchfield; C H Arrowsmith
Journal:  Nat Struct Biol       Date:  1994-12

3.  p53 domains: identification and characterization of two autonomous DNA-binding regions.

Authors:  Y Wang; M Reed; P Wang; J E Stenger; G Mayr; M E Anderson; J F Schwedes; P Tegtmeyer
Journal:  Genes Dev       Date:  1993-12       Impact factor: 11.361

4.  p53 binds single-stranded DNA ends through the C-terminal domain and internal DNA segments via the middle domain.

Authors:  G Bakalkin; G Selivanova; T Yakovleva; E Kiseleva; E Kashuba; K P Magnusson; L Szekely; G Klein; L Terenius; K G Wiman
Journal:  Nucleic Acids Res       Date:  1995-02-11       Impact factor: 16.971

5.  High-resolution structure of the oligomerization domain of p53 by multidimensional NMR.

Authors:  G M Clore; J G Omichinski; K Sakaguchi; N Zambrano; H Sakamoto; E Appella; A M Gronenborn
Journal:  Science       Date:  1994-07-15       Impact factor: 47.728

6.  The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots.

Authors:  N P Pavletich; K A Chambers; C O Pabo
Journal:  Genes Dev       Date:  1993-12       Impact factor: 11.361

7.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.

Authors:  Y Cho; S Gorina; P D Jeffrey; N P Pavletich
Journal:  Science       Date:  1994-07-15       Impact factor: 47.728

8.  Allosteric activation of latent p53 tetramers.

Authors:  T R Hupp; D P Lane
Journal:  Curr Biol       Date:  1994-10-01       Impact factor: 10.834

9.  Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants.

Authors:  T D Halazonetis; A N Kandil
Journal:  EMBO J       Date:  1993-12-15       Impact factor: 11.598

10.  The dihedral symmetry of the p53 tetramerization domain mandates a conformational switch upon DNA binding.

Authors:  J L Waterman; J L Shenk; T D Halazonetis
Journal:  EMBO J       Date:  1995-02-01       Impact factor: 11.598

View more
  27 in total

1.  A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants.

Authors:  Assaf Friedler; Lars O Hansson; Dmitry B Veprintsev; Stefan M V Freund; Thomas M Rippin; Penka V Nikolova; Mark R Proctor; Stefan Rüdiger; Alan R Fersht
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-08       Impact factor: 11.205

Review 2.  Hsp70 interactions with the p53 tumour suppressor protein.

Authors:  M Zylicz; F W King; A Wawrzynow
Journal:  EMBO J       Date:  2001-09-03       Impact factor: 11.598

3.  Evidence of a Prion-Like Transmission of p53 Amyloid in Saccharomyces cerevisiae.

Authors:  Shinjinee Sengupta; Samir K Maji; Santanu K Ghosh
Journal:  Mol Cell Biol       Date:  2017-08-28       Impact factor: 4.272

4.  The structure of p53 tumour suppressor protein reveals the basis for its functional plasticity.

Authors:  Andrei L Okorokov; Michael B Sherman; Celia Plisson; Vera Grinkevich; Kristmundur Sigmundsson; Galina Selivanova; Jo Milner; Elena V Orlova
Journal:  EMBO J       Date:  2006-10-19       Impact factor: 11.598

5.  The C terminus of p53 family proteins is a cell fate determinant.

Authors:  Kelly Lynn Harms; Xinbin Chen
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

6.  Recognition of RNA by the p53 tumor suppressor protein in the yeast three-hybrid system.

Authors:  Kasandra J-L Riley; Laura A Cassiday; Akash Kumar; L James Maher
Journal:  RNA       Date:  2006-04       Impact factor: 4.942

Review 7.  Awakening guardian angels: drugging the p53 pathway.

Authors:  Christopher J Brown; Sonia Lain; Chandra S Verma; Alan R Fersht; David P Lane
Journal:  Nat Rev Cancer       Date:  2009-12       Impact factor: 60.716

8.  Therapeutic strategies for head and neck cancer based on p53 status.

Authors:  Ichiro Ota; Noritomo Okamoto; Katsunari Yane; Akihisa Takahashi; Takashi Masui; Hiroshi Hosoi; Takeo Ohnishi
Journal:  Exp Ther Med       Date:  2012-02-03       Impact factor: 2.447

9.  Mutations in APC, Kirsten-ras, and p53--alternative genetic pathways to colorectal cancer.

Authors:  Gillian Smith; Francis A Carey; Julie Beattie; Murray J V Wilkie; Tracy J Lightfoot; Jonathan Coxhead; R Colin Garner; Robert J C Steele; C Roland Wolf
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-01       Impact factor: 11.205

10.  Aging-associated truncated form of p53 interacts with wild-type p53 and alters p53 stability, localization, and activity.

Authors:  Lynette Moore; Xiongbin Lu; Nader Ghebranious; Stuart Tyner; Lawrence A Donehower
Journal:  Mech Ageing Dev       Date:  2007-11-01       Impact factor: 5.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.